ZA201405204B - Immunogens for hiv vaccination - Google Patents

Immunogens for hiv vaccination

Info

Publication number
ZA201405204B
ZA201405204B ZA2014/05204A ZA201405204A ZA201405204B ZA 201405204 B ZA201405204 B ZA 201405204B ZA 2014/05204 A ZA2014/05204 A ZA 2014/05204A ZA 201405204 A ZA201405204 A ZA 201405204A ZA 201405204 B ZA201405204 B ZA 201405204B
Authority
ZA
South Africa
Prior art keywords
immunogens
hiv vaccination
vaccination
hiv
Prior art date
Application number
ZA2014/05204A
Other languages
English (en)
Inventor
Llano Anuska
Mothe Pujadas Beatriz
Brander Christian
Original Assignee
Institució Catalana De Recerca I Estudis Avançats
Fundació Privada Inst De Recerca De La Sida - Caixa
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institució Catalana De Recerca I Estudis Avançats, Fundació Privada Inst De Recerca De La Sida - Caixa, Esteve Labor Dr filed Critical Institució Catalana De Recerca I Estudis Avançats
Publication of ZA201405204B publication Critical patent/ZA201405204B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2014/05204A 2012-01-27 2014-07-16 Immunogens for hiv vaccination ZA201405204B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382031.8A EP2620446A1 (en) 2012-01-27 2012-01-27 Immunogens for HIV vaccination
PCT/EP2013/051596 WO2013110818A2 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Publications (1)

Publication Number Publication Date
ZA201405204B true ZA201405204B (en) 2015-10-28

Family

ID=47603800

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/05204A ZA201405204B (en) 2012-01-27 2014-07-16 Immunogens for hiv vaccination

Country Status (16)

Country Link
US (4) US9988425B2 (enExample)
EP (3) EP2620446A1 (enExample)
JP (2) JP6306514B2 (enExample)
KR (2) KR102108149B1 (enExample)
CN (2) CN110372798A (enExample)
AU (2) AU2013213564B2 (enExample)
BR (1) BR112014018396B1 (enExample)
CA (1) CA2862172C (enExample)
ES (1) ES2932407T3 (enExample)
IL (2) IL233771B (enExample)
IN (1) IN2014DN06164A (enExample)
MX (2) MX358711B (enExample)
NZ (3) NZ723229A (enExample)
RU (2) RU2648791C2 (enExample)
WO (1) WO2013110818A2 (enExample)
ZA (1) ZA201405204B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US10072046B2 (en) * 2014-03-21 2018-09-11 Nutech Ventures Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using
ES2930667T3 (es) 2014-07-11 2022-12-21 Gilead Sciences Inc Moduladores de receptores de tipo Toll para el tratamiento de VIH
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US20220218711A1 (en) * 2019-05-22 2022-07-14 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
AU2020279988A1 (en) * 2019-05-22 2021-12-23 Aelix Therapeutics, S.L. Dosage regimens for vaccines
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CN116322757A (zh) * 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案
CA3182703A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
PH12023500016A1 (en) 2021-01-14 2024-03-11 Gilead Sciences Inc Hiv vaccines and methods of using
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
EP4417974A1 (en) 2023-02-17 2024-08-21 Fundació Privada Institut de Recerca de la SIDA-Caixa Cd33 as a biomarker of hiv control
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US6610476B1 (en) 1984-08-22 2003-08-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of HIV-1 DNA
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en) 1992-09-16 2008-01-15 Board Of Regents, The University Of Texas System Compositions and methods for eliciting immune or anti-infective responses
KR960703136A (ko) 1993-06-09 1996-06-19 미첼 클레인 탠덤 합성 hiv-1 펩티드들
MX9704765A (es) 1994-12-24 1998-02-28 Univ Cambridge Tech Mejoras en o que se relacionan con la funcion endometrial.
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
CN1233187A (zh) 1996-08-09 1999-10-27 病毒技术公司 HIVp－17肽片段、含有该片段的组合物及其制造和使用方法
US6031647A (en) 1996-10-23 2000-02-29 Nortel Networks Corporation Stable power control for optical transmission systems
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
PT1240186E (pt) * 1999-12-23 2010-03-25 Int Aids Vaccine Initiative Melhorias em respostas imunitárias ou relacionadas com respostas imunitárias ao hiv
FR2803307A1 (fr) * 1999-12-30 2001-07-06 Centre Nat Rech Scient Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1312275A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸
WO2001082964A1 (en) 2000-04-28 2001-11-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
DE60026199T2 (de) 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
EP2302059A1 (en) 2000-08-14 2011-03-30 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization
DK1335987T4 (en) 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
MXPA04002631A (es) 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
JP2005533752A (ja) 2002-03-19 2005-11-10 パウダーメド リミテッド Ｈｉｖｄｎａワクチン接種におけるアジュバントとしてのイミダゾキノリンアミン
RU2238946C2 (ru) * 2002-04-22 2004-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CA2812019A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
CN1982332A (zh) 2002-05-16 2007-06-20 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白
AU2003245729A1 (en) 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
JP2007537975A (ja) * 2003-06-10 2007-12-27 ザ　ユニバーシティー　オブ　メルボルン 免疫調節性組成物、それらについての使用方法およびそれらの製造のための方法
EP2371387A3 (en) 2003-09-17 2012-01-25 Duke University HIV consensus sequence antigens and their use in vaccina
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
CA2539864A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
WO2005047483A2 (en) 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
WO2006010106A2 (en) * 2004-07-09 2006-01-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Dna-based vaccination of retroviral-infected individuals undergoing treatment
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
CA2578403C (en) 2004-08-27 2016-04-05 Bernard Moss Recombinant mva viruses expressing clade a/g, clade b, and clade c modified hiv env, gag and pol genes
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en) 2004-10-29 2006-07-20 Microsoft Corporation Association-based epitome design
CA2853335A1 (en) 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
JP2009500454A (ja) * 2005-07-11 2009-01-08 グローブイミューン， インコーポレイテッド 標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
AU2007226430B2 (en) 2006-03-10 2013-08-29 Peptcell Limited Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
CA2670804A1 (en) 2006-05-19 2007-11-29 Sanofi Pasteur Inc. Immunological composition
CN101563463B (zh) 2006-08-25 2013-03-27 美国国有健康与人类服务部(马里兰州) 修饰的安卡拉（mva）痘苗病毒基因的基因组中保守基因之间的基因间位点
US8198082B2 (en) 2007-03-28 2012-06-12 Hiroshima University Method of determining chicken embryonic stem cells
JP5345135B2 (ja) * 2007-04-26 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション 昆虫細胞のための合成の発現ベクター
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
WO2009089568A1 (en) 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
RU2539765C2 (ru) * 2008-07-16 2015-01-27 Бейлор Рисёч Инститьют ВИЧ ВАКЦИНА, ОСНОВАННАЯ НА НАПРАВЛЕННОСТИ МАКСИМИЗИРОВАННЫХ Gag И Nef НА ДЕНДРИТНЫЕ КЛЕТКИ
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
US8709775B2 (en) 2008-08-29 2014-04-29 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
JP5694945B2 (ja) * 2008-11-18 2015-04-01 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 細胞性免疫原性が向上した抗ウイルスワクチン
JP2013505256A (ja) 2009-09-17 2013-02-14 サノフィ パストゥール インコーポレイテッド Ｈｉｖ用の免疫学的組成物
JP2013507107A (ja) * 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
CA2777744C (en) 2009-10-16 2019-09-24 Bernard Moss Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
WO2011082422A2 (en) 2010-01-04 2011-07-07 The Johns Hopkins University Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2620446A1 (en) * 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
AU2020279988A1 (en) 2019-05-22 2021-12-23 Aelix Therapeutics, S.L. Dosage regimens for vaccines
US20220218711A1 (en) 2019-05-22 2022-07-14 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
CN116322757A (zh) 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案

Also Published As

Publication number Publication date
KR102108149B1 (ko) 2020-05-12
JP6306514B2 (ja) 2018-04-04
MX358711B (es) 2018-08-31
CA2862172A1 (en) 2013-08-01
IN2014DN06164A (enExample) 2015-08-21
US20180170971A1 (en) 2018-06-21
AU2018203264A1 (en) 2018-05-31
EP2807185B1 (en) 2022-09-14
HK1204632A1 (en) 2015-11-27
RU2018104969A3 (enExample) 2019-02-22
AU2013213564A1 (en) 2014-09-04
RU2018104969A (ru) 2019-02-22
NZ723229A (en) 2019-03-29
WO2013110818A2 (en) 2013-08-01
CN104080800B (zh) 2019-08-27
US11325946B2 (en) 2022-05-10
ES2932407T3 (es) 2023-01-18
RU2014135053A (ru) 2016-03-27
US11919926B2 (en) 2024-03-05
BR112014018396B1 (pt) 2023-03-21
CN110372798A (zh) 2019-10-25
US10815278B2 (en) 2020-10-27
US20210246172A1 (en) 2021-08-12
MX2018010483A (es) 2020-09-02
KR102140778B1 (ko) 2020-08-06
JP6749357B2 (ja) 2020-09-02
CN104080800A (zh) 2014-10-01
EP4163290A1 (en) 2023-04-12
WO2013110818A3 (en) 2013-11-07
CA2862172C (en) 2023-07-18
US20150050310A1 (en) 2015-02-19
IL233771B (en) 2019-08-29
BR112014018396A8 (pt) 2017-07-11
KR20140122735A (ko) 2014-10-20
KR20190085552A (ko) 2019-07-18
AU2018203264B2 (en) 2019-07-11
NZ628756A (en) 2016-12-23
RU2721274C2 (ru) 2020-05-18
IL233771A0 (en) 2014-09-30
EP2620446A1 (en) 2013-07-31
IL268629A (en) 2019-10-31
IL268629B (en) 2021-06-30
JP2015509707A (ja) 2015-04-02
AU2013213564B2 (en) 2018-03-29
RU2648791C2 (ru) 2018-04-02
EP2807185A2 (en) 2014-12-03
MX2014009091A (es) 2014-11-10
BR112014018396A2 (enExample) 2017-06-20
US20190055289A1 (en) 2019-02-21
JP2018102314A (ja) 2018-07-05
US9988425B2 (en) 2018-06-05
NZ734689A (en) 2022-09-30

Similar Documents

Publication Publication Date Title
IL268629B (en) Hiv immunogens for use in anti-vaccination
IL235890A0 (en) vaccine
PL2647387T3 (pl) Kompozycja szczepionki
GB201223386D0 (en) Vaccine
EP2806772A4 (en) brewing
SG11201500412TA (en) Vaccine compositions
IL231043A (en) vaccine
SG11201500396TA (en) Tumor vaccination
SG11201403957WA (en) Kit for producing a vaccine
IL234604A (en) Carbon-glycophide vaccines are vaccinated
ZA201500656B (en) Marker vaccine
SI2931304T1 (sl) Cepivo proti WT1
ZA201408840B (en) Stabilized gp120
GB201119999D0 (en) Vaccine
ZA201306245B (en) Combination vaccines
PL2702983T3 (pl) Sposób wytwarzania półstałego preparatu zawierającego bispirydynioalkan
PL2852614T3 (pl) Szczepionka oparta na składniku dopełniacza - C5A
ZA201404512B (en) Malaria vaccine
GB201219420D0 (en) Staphyloccal immunogens
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
GB201120000D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
HUE052963T2 (hu) Készlet vakcina elõállításához
GB201217321D0 (en) Vaccine